Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16009116 | 0.88 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31753134 | 0.88 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL29478732 | 0.83 | HSD17B10 (0.38) | KDM4EALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL21201180 | 0.83 | HSD17B10 (0.38) | KDM4EALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL29426991 | 0.78 | SMN1; SMN2 (0.41) | KDM4EALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL571943 | 0.78 | SMN1; SMN2 (0.41) | KDM4EALDH1A1SMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL24706908 | 0.78 | ASIC3 (0.35) | KDM4E | |
| SCHEMBL30001151 | 0.78 | ASIC3 (0.35) | KDM4E | |
| SCHEMBL23916519 | 0.77 | KDM4E (0.33) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL20875536 | 0.76 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-10-14 | — | — | US | disclosed |
| EP-3558972-A1 | TETRAZOLE CONTAINING COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018114783-A1 | TETRAZOLE CONTAINING COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317092-A1 | TETRAZOLE CONTAINING COMPOUNDS | TSLP, IL5, TRPA1 | KDM4E 4547/4885ALDH1A1 485/4885SMN1; SMN2 1332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.